Safer prescribing of therapeutic norethisterone for women at risk of venous thromboembolism

Diana Mansour
The journal of family planning and reproductive health care · 2012 · vol. 38(3) , pp. 148–149 · doi:10.1136/jfprhc-2012-100345 · PMID:22691698 · W2168837492
Other OA: bronze CC0
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-10-06 ⓘ

This paper reviews the association between high-dose therapeutic norethisterone, used for conditions like endometriosis, and an increased incidence of venous thromboembolism.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

More than 794 000 prescriptions are written for therapeutic (as opposed to contraceptive) use of norethisterone (or its synonym norethindrone) in the UK each year (data on file, Bayer plc). Although its licensed indications include “metropathia haemorrhagica, premenstrual syndrome, postponement of menstruation, endometriosis, menorrhagia and dysmenorrhea”1 most clinicians prescribe it to stop an episode of heavy menstrual bleeding or use it ‘off-label’ to help regulate irregular bleeding associated with hormonal contraception such as progestogen-only implants or injectables.2 In these situations, the dose prescribed is generally 10–20 mg per day, compared to the 0.5–1 mg per day in contraceptive formulations. Some have called therapeutic norethisterone a ‘lifestyle’ drug as its seasonal prescribing peaks during the UK summer months suggest an increased use solely for delaying menstruation during holidays.3 High-dose (therapeutic) norethisterone was thought to be free of serious adverse effects. Doubts, however, first started to emerge in 1999 when two studies4 ,5 reported an increased incidence of venous thromboembolism (VTE) in women taking high-dose oral progestogens for therapeutic indications. No particular progestogen was named but the authors cautioned …

My notes (saved in your browser only)

Condition tags

endometriosisdysmenorrhea

MeSH descriptors

Contraceptives, Oral, Synthetic Norethindrone Venous Thromboembolism Contraceptives, Oral, Synthetic Contraceptives, Oral, Synthetic Dose-Response Relationship, Drug Female Humans Norethindrone Norethindrone Risk Factors Venous Thromboembolism Venous Thromboembolism

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (16)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:10:28.861444+00:00
License: CC0 · commercial use OK